1. Home
  2. Directory
  3. Maryland
  4. Hagerstown
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1821018821

MICHAEL J MCCORMACK M.D
Prescription History 1821018821
Internal Medicine - Medical Oncology in Hagerstown, MD

NPI Status: Active since July 20, 2006

Contact Information

11110 MEDICAL CAMPUS RD
STE 130
HAGERSTOWN, MD
ZIP 21742
Phone: (301) 665-4731
Fax: (301) 665-4711

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHAEL J MCCORMACK M.D, an active Medical Oncology specialist practicing in Hagerstown, MD. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 87 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 32 claims alone.

Medication Index

A
I
T
V
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 94.0
Days Supply 2,820
MD State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills150.7
Peer Average Days Supply4,508
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,448.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.27

State Avg Cost Per Claim

$27.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ibrance

Generic Formulation: PalbociclibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
MD State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.4
Peer Average Days Supply683
Conservative Utilization

This provider writes prescriptions for this formulation 36.0% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $259,410.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,213.18

State Avg Cost Per Claim

$14,356.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 59.3
Days Supply 1,780
MD State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills77.3
Peer Average Days Supply2,312
Conservative Utilization

This provider writes prescriptions for this formulation 32.3% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $557.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.55

State Avg Cost Per Claim

$34.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 585
MD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills30.8
Peer Average Days Supply746
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $700.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.94

State Avg Cost Per Claim

$52.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHAEL J MCCORMACK M.D provides transparency into local medical care patterns within Hagerstown, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.